CN102085361A - 原料含有水蛭素、纤溶素的药物的用途 - Google Patents
原料含有水蛭素、纤溶素的药物的用途 Download PDFInfo
- Publication number
- CN102085361A CN102085361A CN 201110007692 CN201110007692A CN102085361A CN 102085361 A CN102085361 A CN 102085361A CN 201110007692 CN201110007692 CN 201110007692 CN 201110007692 A CN201110007692 A CN 201110007692A CN 102085361 A CN102085361 A CN 102085361A
- Authority
- CN
- China
- Prior art keywords
- hirudin
- medicine
- hyaluronidase
- fibrinolytic
- enteric coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 102000007625 Hirudins Human genes 0.000 title claims abstract description 54
- 108010007267 Hirudins Proteins 0.000 title claims abstract description 54
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 title claims abstract description 54
- 229940006607 hirudin Drugs 0.000 title claims abstract description 54
- 101710084517 Hementerin Proteins 0.000 title abstract 3
- 108010003272 Hyaluronate lyase Proteins 0.000 claims abstract description 51
- 102000001974 Hyaluronidases Human genes 0.000 claims abstract description 51
- 229960002773 hyaluronidase Drugs 0.000 claims abstract description 51
- 206010046798 Uterine leiomyoma Diseases 0.000 claims abstract description 35
- 239000003527 fibrinolytic agent Substances 0.000 claims description 49
- 230000003480 fibrinolytic effect Effects 0.000 claims description 49
- 239000002994 raw material Substances 0.000 claims description 24
- 239000002775 capsule Substances 0.000 claims description 20
- 238000012360 testing method Methods 0.000 abstract description 22
- 241000700159 Rattus Species 0.000 abstract description 8
- 230000000144 pharmacologic effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 description 10
- 208000029312 Muscular tumor Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000002357 endometrial effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 208000007106 menorrhagia Diseases 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 229930193207 hypoglycin Natural products 0.000 description 2
- OOJZCXFXPZGUBJ-RITPCOANSA-N hypoglycin Chemical compound OC(=O)[C@@H](N)C[C@H]1CC1=C OOJZCXFXPZGUBJ-RITPCOANSA-N 0.000 description 2
- OOJZCXFXPZGUBJ-UHFFFAOYSA-N hypoglycin A Natural products OC(=O)C(N)CC1CC1=C OOJZCXFXPZGUBJ-UHFFFAOYSA-N 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004190 broad ligament Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100076929A CN102085361B (zh) | 2011-01-14 | 2011-01-14 | 原料含有水蛭素、纤溶素的药物的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100076929A CN102085361B (zh) | 2011-01-14 | 2011-01-14 | 原料含有水蛭素、纤溶素的药物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102085361A true CN102085361A (zh) | 2011-06-08 |
CN102085361B CN102085361B (zh) | 2012-11-28 |
Family
ID=44097522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100076929A Active CN102085361B (zh) | 2011-01-14 | 2011-01-14 | 原料含有水蛭素、纤溶素的药物的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102085361B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911250A (zh) * | 2006-08-21 | 2007-02-14 | 北京润德康医药技术有限公司 | 一种以水蛭提取物为活性成分的中药肠溶口服制剂及其制备方法 |
-
2011
- 2011-01-14 CN CN2011100076929A patent/CN102085361B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911250A (zh) * | 2006-08-21 | 2007-02-14 | 北京润德康医药技术有限公司 | 一种以水蛭提取物为活性成分的中药肠溶口服制剂及其制备方法 |
Non-Patent Citations (6)
Title |
---|
《中医药信息》 20030131 潘贺,刚宏林,苏云明 《中药水蛭的活性成分及药理作用研究概况》 第20-22页 1-6 第23卷, 第1期 * |
《中医药信息》 20070131 第1期 《水蛭在妇科临床的应用》 第38-39页 1-6 第24卷, 第1期 * |
《中国民族民间医药杂志》 20031230 郭芸 《水蛭在妇科疾病的应用》 第35-37页 1-6 , 第60期 * |
《时珍国医国药》 20020630 刘贞丽,潘继富,董传海 《水蛭的药理作用及其临床应用》 第376-377页 1-6 第13卷, 第6期 * |
《浙江实用医学》 19970830 陈淑莹等 《水蛭的药效学及临床研究进展》 1-6 第2卷, 第4期 * |
《辽宁中医学院生药学专业博士学位论文》 20050727 刘君 《蚂蝗抗凝血的活性成分研究》 第7-8页 1-6 , * |
Also Published As
Publication number | Publication date |
---|---|
CN102085361B (zh) | 2012-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kuijsters et al. | Uterine peristalsis and fertility: current knowledge and future perspectives: a review and meta-analysis | |
Kim et al. | Rejuvenation using platelet-rich plasma and lipofilling for vaginal atrophy and lichen sclerosus | |
CN101002912B (zh) | 用于治疗痛经的月舒滴丸制备方法 | |
CN104857478A (zh) | 一种治疗子宫肌瘤的药物组合物及其制备方法 | |
CN106692946A (zh) | 一种缓解阴道松弛的组合物及其制剂和制法 | |
Bafor et al. | A role of alpha-tocopherol and phylloquinone in the modulation of uterine contractility and reproductive function in mouse models | |
CN102085361B (zh) | 原料含有水蛭素、纤溶素的药物的用途 | |
CN101549122B (zh) | 一种治疗子宫肌瘤的药物组合物 | |
CN114225011B (zh) | 一种用于预防和治疗gsm的复合制剂及其应用 | |
CN112675289B (zh) | 短肽Asp-His-Tyr在制备治疗子宫内膜异位症的药物中的应用 | |
Yamaguchi et al. | A novel animal model of long-term sustainable anal sphincter dysfunction | |
CN101327304A (zh) | 宁泌泰在治疗妇科炎症药物中的用途 | |
Baird et al. | The effect of tracheal occlusion on lung branching in the rat nitrofen CDH model | |
CN113041336A (zh) | 治疗卵巢早衰的中药组合物及其制备方法、应用 | |
CN103656431A (zh) | 一种治疗子宫肌瘤的中药 | |
Li et al. | Effects of moxibustion at different times on prostaglandin and vasopressin levels in uterine tissues of rats with dysmenorrhea due to cold-dampness retention | |
CN113244368B (zh) | 多肽在制备治疗子宫内膜异位症的药物中的应用 | |
CN112353933B (zh) | 一种预防和/或治疗子宫肌瘤的药物及其制备方法 | |
CN105769915A (zh) | 阿胶在制备治疗不孕不育药物或保健品中的用途 | |
CN103656430A (zh) | 一种治疗女性子宫肌瘤的中药 | |
Min | Transvaginal Myomectomy for A Huge Cervical Myoma with Cervical Cyst: A Case Report and Review of the Literature | |
Qizi | Safe Grow Of The Uterus | |
CN103656517A (zh) | 一种治疗子宫肌瘤的中药配方 | |
CN104815310A (zh) | 一种清除胚胎组织残留的药物 | |
EP2903631B1 (en) | Use of degarelix in the treatment of endometriosis and related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Applicant after: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. Address before: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Applicant before: CHONGQING SHIZHENGE PUSHENG PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHONGQING SHIZHEN'GE PUSHENG PHARMACEUTICAL CO., LTD. TO: CHONGQING DUOPUTAI PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Cao Jia Dian 400800 Chongqing city Wansheng District East Qingxi Bridge Patentee after: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. Address before: Cao Jia Dian 400802 Chongqing city Wansheng District East Qingxi Bridge Patentee before: Chongqing Duoputai Pharmaceutical Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240112 Address after: No. 303-7, Qingxi Bridge, Donglin Street, Wansheng Economic Development Zone, Qijiang District, Chongqing, 400800 Patentee after: Chongqing Duoputai Pharmaceutical Technology Co.,Ltd. Address before: 400800 Donglin Qingxi bridge in Wansheng District, Chongqing Patentee before: CHONGQING DUOPUTAI PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |